X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Merck to Acquire Verona

    Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

    Emerging Oral Small Molecule Drugs

    Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Merck to Acquire Verona

    Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

    Emerging Oral Small Molecule Drugs

    Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

Heart Attack To Be Cured With COVID-19 Tech By Kings College

Content Team by Content Team
24th April 2022
in News
FDA Approves Ticagrelor to Reduce Risk of First Heart Attack, Stroke in Patients with Coronary Artery Disease

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

King’s College London, a public research university, is using messenger RNA (mRNA) technology to battle the physiological effects of cardiac arrest in the hopes of developing the world’s first heart attack treatment. The technology has the ability to reverse cardiac damage to a large extent.

Such has been the devastating effect of COVID-19 that the NHS has launched a new life-saving campaign in the hopes of preventing any unforeseen and terrible events such as chest tightness, excessive fatigue, and uneasiness, all of which point to a heart-related issue. 

mRNAs are biological codes that result in the production of proteins containing genetic information. King’s College University’s mRNA technology creates proteins that stimulate the formation of healthy new heart cells and can be administered straight to the heart muscle following an attack. The proteins produced by the technology can help the heart muscle regenerate cells. This revolutionary response has yet to be included in any cardiac drugs or post-episode treatments.

If we talk about the US in particular, one out of every four Americans has heart problems that have developed due to a COVID-19 history. Since the beginning of the pandemic, 41% of Americans have had at least one cardiac problem.

People are all born with a specific number of muscle cells in their hearts, and they are exactly the same ones they will die with, says professor of cardiovascular sciences at King’s College’s School of Cardiovascular Medicine and Sciences, Mauro Giacca. The goal has been to develop a way to persuade surviving cells to multiply. He added that they are injecting micro RNAs into the heart using the same technique as Pfizer and Moderna vaccines, targeting living heart cells and boosting their multiplication.

The level of cardiac treatment might be dramatically enhanced, and the lives of millions of people throughout the world could be extended, if the technology progresses to regulatory approval with guidelines for heart attack patients.

As a result of the research, proteins that may be delivered to heart attack patients in the rear of an ambulance to protect heart cells from dying have also been discovered.

Previous Post

Can Novartis Thrive In US-EU Post BeiGene PD-1 China Nod

Next Post

Industry Minister- Indian Pharma Should Focus On Generics

Related Posts

Merck to Acquire Verona
Drug Development

Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

21st July 2025
ChiRhoClin LogiCare3PL Partners for Drug Distribution
News

ChiRhoClin, LogiCare3PL Partners for Drug Distribution

21st July 2025
Thermo Fisher and Sanofi Partners
Manufacturing

Thermo Fisher and Sanofi Partners for US Drug Manufacturing

21st July 2025
EMA Recommendations to Secure Anti D Immunoglobulins Supply
News

EMA Recommendations to Secure Anti-D Immunoglobulins Supply

15th July 2025
FDA Approves Oral Therapy for Treating Hereditary Angioedema
FDA Approvals

FDA Approves Oral Therapy for Treating Hereditary Angioedema

15th July 2025
WuXi Biologics and Virogen Bio partner to advance VG712
News

WuXi Biologics and Virogen Bio partner to advance VG712

19th June 2025
Next Post
Charities Pay $6 Million to Settle Medicare Kickback Allegations in Pharma Probe

Industry Minister- Indian Pharma Should Focus On Generics

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In